Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Trevor Parry, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Claims28
A pharmaceutical composition for topical, transdermal, superficial, or intradermal administration comprising:
- (a) a herpes simplex virus comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises a first polynucleotide encoding a first cosmetic protein and a second polynucleotide encoding a second cosmetic protein;
- and
- (b) a pharmaceutically acceptable excipient;
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in both copies of the Infected Cell Protein (ICP4) herpes simplex virus gene;
- wherein the first cosmetic protein is selected from the group consisting of a first collagen protein, a first fibronectin protein, a first elastin protein, a first lumican protein, a first vitronectin protein, a first vitronectin receptor protein, a first laminin protein, a first neuromodulator protein, and a first fibrillin protein;
- and
- wherein the recombinant herpes simplex virus genome does not comprise a polynucleotide encoding a Collagen alpha-1 (VII) chain polypeptide (COL7).
A method of improving skin condition, quality, and/or appearance in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising:
- (a) a herpes simplex virus comprising a recombinant herpes virus simplex genome, wherein the recombinant herpes simplex virus genome comprises a first polynucleotide encoding a first cosmetic protein and a second polynucleotide encoding a second cosmetic protein;
- and
- (b) a pharmaceutically acceptable excipient;
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in both copies of the ICP4 herpes simplex virus gene;
- wherein the first cosmetic protein is selected from the group consisting of a first collagen protein, a first fibronectin protein, a first elastin protein, a first lumican protein, a first vitronectin protein, a first vitronectin receptor protein, a first laminin protein, a first neuromodulator protein, and a first fibrillin protein;
- wherein the recombinant herpes simplex virus genome does not comprise a polynucleotide encoding a Collagen alpha-1 (VII) chain polypeptide (COL7);
- wherein the pharmaceutical composition is administered topically, transdermally, intradermally, or via superficial injection to the subject;
- wherein the recombinant herpes simplex virus genome is delivered to one or more target cell of the skin of a subject;
- and
- wherein the first cosmetic protein is expressed in one or more target cells of the skin of a subject.
Dependencies are inferred from the claim text.